Sulagshan Mahendrarajah, MD
Neurology · Medford, ORNPI 1043508070
Payments from drug & device makers
Across 218 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$340
- Biogen$276
- Pfizer$242
- Argenx US, Inc.$186
- Novartis$178
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,319100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,250 |
| Lundbeck LLC | 17 | $340 |
| Biogen | 14 | $276 |
| Pfizer | 14 | $242 |
| Argenx US, Inc. | 7 | $186 |
| Novartis | 9 | $178 |
| UCB, Inc. | 6 | $163 |
| SK Life Science, Inc. | 8 | $136 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $130 |
| Neurocrine Biosciences, Inc. | 6 | $118 |
| Acadia Pharmaceuticals Inc | 6 | $105 |
| Teva Pharmaceuticals USA, Inc. | 5 | $100 |
| Eisai Inc. | 5 | $99 |
| GE HealthCare | 5 | $86 |
| Lilly USA, LLC | 4 | $82 |
| Genentech USA, Inc. | 4 | $81 |
| Amgen | 4 | $74 |
| Novo Nordisk | 1 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| AstraZeneca | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 8 | $59 |
| Jazz Pharmaceuticals Inc. | 2 | $52 |
| GRT US Holding, Inc. | 4 | $45 |
| Neurelis, Inc. | 1 | $32 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| MDD US Operations, LLC | 2 | $27 |
| Medtronic | 1 | $26 |
| EDW Pharma, Inc. | 1 | $25 |
| Amylyx Pharmaceuticals, Inc. | 1 | $23 |
| Adamas Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Averitas Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,319 in reported general payments places this provider in the 70th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 77 | $1,293 |
| Levetiracetam | 40 | $714 |
| Gabapentin | 110 | $605 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $147 |
| Duloxetine Hcl | 12 | $132 |
| Donepezil Hcl | 18 | $90 |
| Ropinirole Hcl | 14 | $86 |
| Quetiapine Fumarate | 14 | $40 |
Paid to pharmacies, not to this prescriber.
Other neurology in Medford
- Walter CarliniMedford$461K
- Robert EganMedford$32K
- Minji KimMedford$28K
- Christopher DardisMedford$12K
- Stanley CohanPortland$3.9M
- Kyle SmootPortland$3.2M
- Aimee PiercePortland$3M
- Chafic KaramPortland$2.8M
- Prakash AmbadyPortland$2.7M
- Michael MegaPortland$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.